Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, Food and PPI Effects of BMS-986365 in Healthy Men
NCT06417229Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986365 in metastatic castration-resistant prostate cancer (mCRPC) (11 cohorts), sponsored by Celgene Corporation. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration and 1 more. Started May 2024; status: completed.
02
Drugs
BMS-986365
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06417229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417229.